Abstract: Proposed are a vehicle seat monopost assembly and a vehicle seat mounted thereon. In one aspect, a drive part includes a housing mounted on a lower frame connected to a vehicle body and a first engagement part configured to be rotated by a drive source. A second engagement part suitably may include a thread configured to be engaged with the first engagement part and a cylindrical body configured to be fixed to a vehicle seat frame. A connecting sleeve part is seated on the drive part and has an inner space into which the lead screw part is fitted. The connecting sleeve part is configured to restrict a rotation in response to an operation of a rotation restricting member.

Abstract: A COTL1 gene or protein maintains and regulates the homeostasis of hematopoietic stem cells. A method of diagnosis and treatment of blood-related disease caused either by abnormalities in the homeostasis of hematopoietic stem cells, which result from a mutation in the COTL1 gene or a decrease in the expression of the COTL1 protein, or by an imbalance between the differentiation or proliferation and damage or death of hematopoietic stem cells, or by abnormalities in mitochondrial homeostasis are disclosed. The COTL1 gene or protein plays an important role in regulating mitochondrial morphology, and when it is knocked down, the number of hematopoietic stem cells decreases.

Abstract: The present invention relates to a composition for diagnosing, preventing, or treating cognitive dysfunction comprising, as an active ingredient, COTL1 protein or a gene encoding same. The COTL1 protein or the gene encoding same of the present invention plays a vital role in mitochondrial morphology regulation. In addition, when the expression thereof is inhibited, learning ability and memory are deteriorated, and when the inhibited expression thereof is recovered, cognitive ability is improved, and thus the COTL1 protein or the gene encoding same can be effectively used in the diagnosis and treatment of cognitive dysfunction.

Abstract: The present invention relates to a composition, comprising COTL1 as an active ingredient, for diagnosis of a bone disease or obesity. Downregulation of the expression of the COTL1 protein or a gene thereof inhibits the differentiation activity of osteoclasts to reinforce bone density, compared to a normal control, and to increase factors that induce articular inflammation and cartilage degeneration, causing a bone disease such as osteosclerosis or osteoarthritis. Thus, COTL1 protein or a gene coding therefor can be used for diagnosing, preventing, or treating a bone disease such as osteosclerosis or osteoarthritis. In addition, downregulation of the expression of COTL1 protein or a gene coding therefor exhibits an excellent effect of treating obesity by reducing body weight and body fat mass in high-fat diet obesity mouse models and suppressing hepatic fat accumulation and adipocyte sizes and can be used for diagnosing obesity.

Abstract: The present invention provides a pharmaceutical composition and health functional food composition for preventing or treating female menopausal disease including extract of Ribes fasciculatum leaves as an active ingredient, and a pharmaceutical composition and health functional food composition for preventing or treating female menopausal disease including an extract of Cornus officinalis and extract of Ribes fasciculatum leaves as active ingredients.

Abstract: The present invention relates to a compound of dihydrophaseic acid 3?-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the Lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling.

Abstract: The present invention relates to a single nucleotide polymorphism marker for precocious puberty diagnosis or treatment prognosis prediction for the disease, and a use thereof. In the present invention, the DNA of 700 girl patients of precocious puberty is processed on a microarray chip containing a total of 8,754,887 SNP probes so that SNP genotype data is obtained, and 23 SNPs related to the risk of developing precocious puberty are discovered by means of genome-wide association analysis so that the SNPs can be used for precocious puberty diagnosis or treatment prognosis prediction, early diagnosis of precocious puberty can be conveniently and rapidly carried out, and the prediction of treatment effects and prognosis can be carried, and thus the present invention can be effectively used in a personalized treatment.

Abstract: A pharmaceutical composition for preventing or treating female climacteric syndromes comprising Loganin which increases the concentration of estradiol (17?-estradiol, E2) in the blood of a menopausal mouse model and has shown efficacies such as an increase in the estrogen receptor alpha expression in the uterus, which remedies uterine contraction and degeneration, and decreases in the accumulation and the size of adipocytes in liver and the abdominal adipose tissues and the liver and weight loss, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention provides a pharmaceutical composition and health functional food composition for preventing or treating female menopausal disease including extract of Ribes fasciculatum leaves as an active ingredient, and a pharmaceutical composition and health functional food composition for preventing or treating female menopausal disease including an extract of Cornus officinalis and extract of Ribes fasciculatum leaves as active ingredients.

Abstract: A COTL1 gene or protein maintains and regulates the homeostasis of hematopoietic stem cells. A method of diagnosis and treatment of blood-related disease caused either by abnormalities in the homeostasis of hematopoietic stem cells, which result from a mutation in the COTL1 gene or a decrease in the expression of the COTL1 protein, or by an imbalance between the differentiation or proliferation and damage or death of hematopoietic stem cells, or by abnormalities in mitochondrial homeostasis. The COTL1 gene or protein plays an important role in regulating mitochondrial morphology, and when it is knocked down, the number of hematopoietic stem cells decreases.

Abstract: Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.

Abstract: A pharmaceutical composition for preventing or treating female climacteric syndromes comprising Loganin which increases the concentration of estradiol (17?-estradiol, E2) in the blood of a menopausal mouse model and has shown efficacies such as an increase in the estrogen receptor alpha expression in the uterus, which remedies uterine contraction and degeneration, and decreases in the accumulation and the size of adipocytes in liver and the abdominal adipose tissues and the liver and weight loss, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention relates to a compound of dihydrophaseic acid 3?-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast.

Abstract: Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.

Abstract: An automatic ice making apparatus for use in a refrigerator has a water regulation container capable of containing water therein and a pair of lateral holes formed on side portions of the water regulation container. The water regulation container is also provided with a drain hole formed through a bottom of the water regulation container and a second conduit through which the water in the water regulation container is delivered to a mold for defining a shape of an ice cube. A micro processor controls an opening and a closing states of the drain hole in such a way that the drain hole is opened for a predetermined time to be closed.